FDA官员Shivana Srivastava在会议开始时按常规流程宣读标准的利益冲突声明，指出Nelson和Goldman以非投票角色参与会议。但随后话锋一转，说道：尽管非投票成员以代表身份参与，但应克制行使该职能，不得进行“不当倡导”或试图对会议其他成员施加“过度影响”（shall exercise restraint in performing such functions and may not engage in unseemly advocacy or attempt to exert undue influence over the other members of the committee）。
